Media Kit
Click the links below to download images and other media assets.
Logos
.svg)
.svg)
.svg)
.svg)
.svg)
.svg)
.svg)
.svg)
.svg)
.svg)
.svg)
.svg)
.png)
.svg)
.svg)
Product imagery
.png)
.png)
.png)
Lifestyle imagery
.png)
.png)
.png)
.png)
About Sequel Med Tech
Headquartered in Manchester, NH, Sequel Med Tech, LLC is developing the next generation of transformative drug-delivery advancements. Sequel’s approach is to look at disease management holistically to advance systems that make living with disease simpler and easier for all. Its FDA-cleared innovation, the twiist™ Automated Insulin Delivery (AID) System, integrates novel technologies to reimagine insulin delivery and sets a new standard for drug delivery. Sequel is bringing the latest developments in science and technology to help drive more accessible drug delivery.
For more information, visit sequelmedtech.com and twiist.com.
About twiist
twiist is a breakthrough in diabetes management. It's the first and only AID System to directly measure the volume of insulin delivered with every microdose, for confidence and control over insulin delivery.
twiist addresses individual dosing needs with twiist Loop, which is based on the FDA-cleared and community-driven Tidepool Loop algorithm. It enables twiist to automatically adjust basal insulin delivery based on CGM readings, personalized settings, and predicted glucose levels.
In addition, twiist offers unique features like pre-meal and activity presets, the widest glucose target range,1-6 and the ability to go back and change a carb entry or the time you ate.
twiist is underpinned by our proprietary iiSure™ Technology, which ensures accurate dosing and detects blockages up to 9x faster* than other AID systems.
twiist is for people with type 1 diabetes, 6 years of age and above, available with a prescription, only in the US. For important safety information, visit twiist.com/safety. For additional details, visit twiist.com.
The assets on this page are intended for U.S. use only.
By using any of the images provided by Sequel Med Tech, LLC (“Sequel”), you agree that (i) the use is personal or editorial and non-commercial; (ii) the images may not be altered or modified in any way, nor may you create derivative works based on the images without written permission from Sequel; and (iii) you will provide the following disclosure for all uses of the images:
- By using any of the images provided by Sequel Med Tech, LLC (“Sequel”), you agree that (i) the use is personal or editorial and non-commercial; (ii) the images may not be altered or modified in any way, nor may you create derivative works based on the images without written permission from Sequel; and (iii) you will provide the following disclosure for all uses of the images:Copyrighted image used with permission. © 2026 Sequel Med Tech, LLC. All rights reserved. twiist and Sequel are trademarks licensed to Sequel Med Tech, LLC in the United States of America.
The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott and used with permission. For full FreeStyle Libre 3 Plus sensor safety information, please visit https://www.freestyle.abbott/us-en/safety-information.html.
The Eversense 365 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to one year in people (18 years and older) with diabetes. For important safety information, see bit.ly/eversensesafety. Eversense, Eversense 365 Continuous Glucose Monitoring, and the Eversense logo are trademarks of Senseonics, Incorporated.
